Painreform Ltd - Asset Resilience Ratio
Painreform Ltd (PRFX) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Painreform Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2023)
This chart shows how Painreform Ltd's Asset Resilience Ratio has changed over time. See PRFX net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Painreform Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PRFX stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Painreform Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Painreform Ltd Industry Peers by Asset Resilience Ratio
Compare Painreform Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Painreform Ltd (2021–2023)
The table below shows the annual Asset Resilience Ratio data for Painreform Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $9.93 Million | -- |
| 2022-12-31 | 49.36% | $6.08 Million | $12.33 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $19.07 Million | -- |
About Painreform Ltd
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinica… Read more